This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.

Unlock the details of this groundbreaking opportunity here...

Srdjan R. Stankovic net worth and biography

Srdjan Stankovic Biography and Net Worth

President of ACADIA Pharmaceuticals

Srdjan (Serge) Stankovic, M.D., M.S.P.H. is our President and responsible for overseeing Research and Development at Acadia. From November 2015 to November 2018 Dr. Stankovic was Executive Vice President, Head of Research and Development. With a background in clinical and academic psychiatry, Dr. Stankovic brings over 20 years of executive level experience in drug development and clinical and medical affairs. Dr. Stankovic has built and led multidisciplinary teams for small molecules and biologics in multiple therapeutic areas including neurology, psychiatry, oncology, cardiology and pain. He has led teams to achieve approvals of KEPPRA®, FENTORA®, TREANDA®, NUVIGIL® and ARISTADA®. Prior to joining Acadia, Dr. Stankovic served as Senior Vice President of Clinical Development and Medical Affairs at Alkermes plc. from 2013 to 2015. Prior to Alkermes, he held the position of Senior Vice President and Head of Global Clinical Development for Teva Pharmaceuticals Ltd. He was appointed to this role following Teva’s acquisition of Cephalon, Inc. where he served as Senior Vice President, Worldwide Clinical Research. Dr. Stankovic also served as Senior Vice President, Medical Affairs and Clinical Development CNS at Forest Laboratories, Inc. and held executive positions in research and development at Neurogen Corporation (now Ligand Pharmaceuticals), Johnson and Johnson, and UCB. He currently serves on the Board of Directors at Neurogene, Inc. Dr. Stankovic received his M.D. from the University of Belgrade and holds a Master of Science in Public Health from the University of Alabama at Birmingham.

What is Srdjan R. Stankovic's net worth?: The estimated net worth of Srdjan R. Stankovic is at least $998,726.54 as of November 21st, 2022. Dr. Stankovic owns 61,234 shares of ACADIA Pharmaceuticals stock worth more than $998,727 as of April 25th. This net worth evaluation does not reflect any other investments that Dr. Stankovic may own. Learn More about Srdjan R. Stankovic's net worth.
How do I contact Srdjan R. Stankovic?: The corporate mailing address for Dr. Stankovic and other ACADIA Pharmaceuticals executives is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. ACADIA Pharmaceuticals can also be reached via phone at (858) 558-2871 and via email at [email protected]. Learn More on Srdjan R. Stankovic's contact information.
Has Srdjan R. Stankovic been buying or selling shares of ACADIA Pharmaceuticals?: Srdjan R. Stankovic has not been actively trading shares of ACADIA Pharmaceuticals in the last ninety days. Learn More on Srdjan R. Stankovic's trading history.
Who are ACADIA Pharmaceuticals' active insiders?: ACADIA Pharmaceuticals' insider roster includes Laura Brege (Director), Stephen Davis (CEO), James Kihara (Insider), Austin Kim (EVP), Elena Ridloff (CFO), Mark Schneyer (CFO), Srdjan Stankovic (President), and Brendan Teehan (COO). Learn More on ACADIA Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ACADIA Pharmaceuticals?: During the last year, ACADIA Pharmaceuticals insiders bought shares 1 times. They purchased a total of 209,053 shares worth more than $5,312,036.73. During the last year, insiders at the biopharmaceutical company sold shares 33 times. They sold a total of 337,790 shares worth more than $8,216,006.23. The most recent insider tranaction occured on April, 8th when CEO Stephen Davis sold 26,574 shares worth more than $474,877.38. Insiders at ACADIA Pharmaceuticals own 27.5% of the company. Learn More about insider trades at ACADIA Pharmaceuticals.
Information on this page was last updated on 4/8/2024.

Srdjan R. Stankovic Insider Trading History at ACADIA Pharmaceuticals

Srdjan R. Stankovic Buying and Selling Activity at ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Company Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Today's Range

Now: $16.31

$16.16

$16.51

50 Day Range

MA: $20.29

$16.59

$26.36

2 Week Range

Now: $16.31

$16.16

$33.99

Volume

1,660,612 shs

Average Volume

1,765,577 shs

Market Capitalization

$2.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.37

Jim Cramer’s “The Biggest Drug Ever”

From Behind the Markets | Ad